DocGo Inc.

NASDAQ:DCGO

Medical - Care Facilities

Healthcare
$0.71 -4.29%

-$0.02 today

Market cap
$70.14M
Beta
1.00
P/E (TTM)
-0.3
EPS (TTM)
-$1.90
52W Low $0.49High $1.78

Volume 1.64M

Average 0.87M

DCGO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

DocGo Inc.NASDAQ: DCGO

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns positive

Q1 FY2026 income tax expense was $19.28K, compared with -$3.72M a year earlier. Trailing-twelve-month income tax expense was $12.61M.

Context

  • Income tax expense amounted to 2.8% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $19.28K or moves back toward the trailing-twelve-month quarterly average of $3.15M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.28K-99.9% QoQ
Last fiscal yearDec 2025
$8.87M-38.4% YoY
LTMMar 2026
$12.61M+127.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.5%——
1 year-38.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
8.87M USD
Year-over-year change
-38.4%
4-year CAGR
+94.8%

Income Tax Expense vs competitors

How DCGO compares with its peers on the latest reported figures

  • DCGO's LTM Mar 2026 income tax expense of $12.61M is the highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +127.4% is the highest of 5, against a peer median of -80.9%.
  • Income tax expense amounts to 4.2% of revenue for DCGO, versus a peer median of 0.0%.
DCGO Competitors Peer median
Income Tax Expense for DCGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$12.61M +127.4%—4.2%
IMMXImmix Biopharma, Inc.LTM Mar 2026$27.9K -33.6%+54.3%—
COYACoya Therapeutics, Inc.LTM Mar 2026$3.09K +100.4%—0.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 ——0.0%
VANIVivani Medical, Inc.LTM Mar 2026$0 ———
MBOTMicrobot Medical Inc.LTM Mar 2026$0 ——0.0%
RCELAVITA Medical, Inc.LTM Mar 2026-$9K -128.1%-32.6%0.0%
MGNXMacroGenics, Inc.LTM Mar 2026-$672K -171.2%—0.4%
Peer median (excluding DCGO) $0-80.9%+10.8%0.0%

Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue318.72M440.52M624.29M616.56M322.2M
Cost of Revenue208.97M285.79M428.91M402.98M223.44M
Gross Profit109.75M154.72M195.38M213.57M98.76M
Gross Margin34.4%35.1%31.3%34.6%30.7%
Research & Development3.32M5.38M10.86M11.59M13.56M
Selling, General & Admin83.56M116.94M153.04M157.41M158.69M
Operating Expenses94.39M132.89M180.33M184.89M187.91M
Depreciation & Amortization7.51M10.57M16.43M15.88M15.66M
EBITDA28.07M33.35M32.73M45.56M(170.82M)
EBITDA Margin8.8%7.6%5.2%7.4%-53.0%
Operating Income15.36M21.83M15.05M28.69M(89.16M)
Operating Margin4.8%5.0%2.4%4.7%-27.7%
Interest Income0762.69K1.68M236.95K0
Interest Expense763.03K002.17M1.01M
Other Income / Expenses4.44M950.26K1.24M(939.72K)(98.34M)
Income Before Tax19.8M22.78M16.29M27.75M(187.5M)
Pre-Tax Margin6.2%5.2%2.6%4.5%-58.2%
Income Tax Expense615.7K(7.96M)6.24M14.39M8.87M
Net Income23.74M34.58M6.86M19.99M(182.4M)
Net Margin7.4%7.9%1.1%3.2%-56.6%
EPS (Basic)0.300.340.070.20(1.84)
EPS (Diluted)0.250.340.060.18(1.84)
Weighted Avg Shares80.29M101.23M103.51M102.4M99.07M
Weighted Avg Shares (Diluted)94.86M102.98M105.62M109.42M99.07M

DocGo Inc.

NASDAQ:DCGO

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.